Business Description
Theraclion
ISIN : FR0010120402
Share Class Description:
XPAR:ALTHE: Act.Compare
Compare
Traded in other countries / regions
ALTHE.FranceTCLIF.USA IPO Date
2014-04-17Description
Theraclion is a France-based company specializing in high-tech therapeutic ultrasound equipment. The product, Echopulse, helps in the treatment of breast fibroadenomas and benign thyroid nodules.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.01 | |||||
| Equity-to-Asset | 0.3 | |||||
| Debt-to-Equity | 0.35 | |||||
| Debt-to-EBITDA | -0.95 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 0.36 | |||||
| Beneish M-Score | -0.82 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -6.2 | |||||
| 3-Year EBITDA Growth Rate | 44.3 | |||||
| 3-Year EPS without NRI Growth Rate | 29.1 | |||||
| 3-Year FCF Growth Rate | 36.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.9 | |||||
| 9-Day RSI | 44.21 | |||||
| 14-Day RSI | 42.49 | |||||
| 6-1 Month Momentum % | -16.84 | |||||
| 12-1 Month Momentum % | -47.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.54 | |||||
| Quick Ratio | 2.87 | |||||
| Cash Ratio | 1.72 | |||||
| Days Inventory | 382.06 | |||||
| Days Sales Outstanding | 453.21 | |||||
| Days Payable | 244.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -41.4 | |||||
| Shareholder Yield % | -70.46 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -59.33 | |||||
| Operating Margin % | -172.28 | |||||
| Net Margin % | -201.7 | |||||
| FCF Margin % | -142.54 | |||||
| ROE % | -86.5 | |||||
| ROA % | -20.62 | |||||
| ROIC % | -27.58 | |||||
| ROC (Joel Greenblatt) % | -196.25 | |||||
| ROCE % | -35.85 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.48 | |||||
| PB Ratio | 2.41 | |||||
| Price-to-Tangible-Book | 2.99 | |||||
| EV-to-EBIT | -1.66 | |||||
| EV-to-EBITDA | -3.8 | |||||
| EV-to-Revenue | 4.28 | |||||
| EV-to-FCF | -2.95 | |||||
| Price-to-Median-PS-Value | 0.48 | |||||
| Price-to-Net-Current-Asset-Value | 4.27 | |||||
| Earnings Yield (Greenblatt) % | -60.27 | |||||
| FCF Yield % | -19.02 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers